AVITA Medical’s RECELL Platform Wins 2025 MedTech Breakthrough Award for Surgical Innovation

VALENCIA, Calif. – In a testament to its cutting-edge approach to wound care, AVITA Medical (NASDAQ: RCEL, ASX: AVH) has secured a significant accolade. The company announced today that its RECELL^Ⓡ system, including the innovative RECELL^Ⓡ GO, has been crowned the “Best New Technology Solution – Surgical” in the prestigious 2025 MedTech Breakthrough Awards.

The win underscores the game-changing potential of RECELL, already FDA-approved for treating thermal burns and full-thickness skin defects. With over 30,000 patients treated globally, RECELL distinguishes itself by requiring substantially smaller donor skin grafts than traditional procedures. This translates to less pain at the donor site and consequently, faster recovery times for patients. The clinical advantages don’t end there; RECELL has also demonstrated reduced instances of repeat procedures, leads to better functional and aesthetic outcomes, and often contributes to shortened hospital stays – a win-win for both patients and healthcare providers.

RECELL GO takes this a step further. While retaining all the core benefits, it streamlines the surgical process and enhances coordination within the surgical team, always with the physician at the helm. Designed with high-volume burn and trauma centers in mind, RECELL GO offers a scalable, cost-effective solution across a wide array of acute wound care settings, positioning AVITA Medical well for continued growth.

“We are honored by this recognition, which truly highlights the major benefits that RECELL brings to the world of burn and trauma care,” said Jim Corbett, CEO of AVITA Medical. “By significantly reducing the donor skin needed, RECELL helps reduce patient pain and accelerates the healing process, leading to improved overall outcomes. We are resolute in our mission to expand access to this transformative technology and to revolutionize patient care.”

The MedTech Breakthrough Awards are a respected platform with a global reach, celebrating the innovators and groundbreaking products that are shaping the future of healthcare. The 2025 awards witnessed an overwhelming response, with over 4,500 nominations worldwide, making AVITA Medical’s win even more notable.

Adding to the company’s list of achievements, Dr. Katie Bush, Senior Vice President of Scientific & Medical Affairs at AVITA Medical, has been awarded the 2025 Emerald Pinnacle Healthcare Award in the Medical Device category. The Pinnacle Award specifically honors individuals and companies exhibiting exemplary leadership, deep-seated innovation, and significant positive contributions in the healthcare field.

AVITA Medical, is a leader in therapeutic acute wound care, dedicated to offering groundbreaking solutions that promote faster healing and recovery for its patients. Its flagship technology, the RECELL System^®, is FDA-approved for thermal burn wounds and full-thickness skin defects. RECELL uses a patient’s own skin to create Spray-On Skin^™ Cells, offering an innovative method enhancing clinical outcomes in situ. Beyond its core products, AVITA Medical also holds exclusive rights in the U.S. to PermeaDerm^®, a biosynthetic wound matrix, and Cohealyx^™, a collagen-based dermal matrix, adding to its versatile portfolio.

In markets beyond the US, the RECELL System has been approved for a wide variety of applications, from burn treatments, to full-thickness skin defects, to vitiligo. The RECELL System, excluding RECELL GO^™, is TGA-registered in Australia, holds CE mark approval in Europe, and has also received PMDA approval in Japan.

To learn more, visit www.avitamedical.com.

Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “guidance,” “intend,” “look forward,” “may,” “outlook,” “project,” “target,” “will,” “would,” and similar words or expressions, and the use of future dates. Forward-looking statements include, but are not limited to, statements relating to the timing and realization of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, as well as other economic or political conditions outside of the Company’s control. These statements are made as of the date of this release, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the “Risk Factors” section of the Company’s latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties.

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.